Recent Awards & Honors
Henry Daniell, a professor in the Burnett School of Biomedical Sciences in the College of Medicine, was honored for his “distinguished contributions to the field of chloroplast genetic engineering, to the development of transgenic plants with agronomic traits and field production of vaccine antigens and biopharmaceuticals.”.
Dr. Daniell was elected a member of the Italian National Academy of Sciences at its 222nd annual inauguration in Rome on April 29, 2005. He is the 15th American national to be elected in the history of this academy. Past members include Benjamin Franklin and Albert Einstein.
Daniell is the seventh winner of the annual award that is the most prestigious honor the university gives to a faculty member. The Pegasus Professor Award recognizes excellence in teaching, research and service.
Dr. Daniell is the gold-standard by which all faculty should be compared; he is an extremely accomplished scientist and scholar, a model university leader and citizen, and an effective and compassionate teacher, wrote Alexander Cole, an assistant professor in the Department of Molecular Biology and Microbiology.
Five premier faculty members are making plans to enhance their renowned research with more than $1 million awarded last week to UCF’s first Trustee Chairs.
The appointments of Glenn Boreman, Henry Daniell, Peter Delfyett, Eduardo Salas and Kay Stanney "reward them for doing an outstanding job and provide incentive for them to continue to excel," says Dick Nunis, chair of the UCF Board of Trustees.
Invited presentation, booth/video, Wired Nextfest World Science Fair, One among the top six medical breakthroughs in 2004, Sponsored by GE and Wired magazine, Fort Mason Center, San Francisco, 2004
Dr. Daniell was the invited speaker for the 2004 New Student Convocation.
Chlorogen, Inc., has been selected to receive the Frost and Sullivan 2005 Entrepreneurial Company of the year award. The company, co-founded by Henry Daniell and based on his patented chloroplast technology, was recognized for its success in entering the marketplace at a time when venture capital was limited.
Chlorogen attracted $5 million in funding simultaneously from four leading US venture capital groups in August 2003. The Frost & Sullivan analytical group noted that Chlorogen is entering one of the most commercially promising emerging marketplaces in the life sciences industry and lauded the company for innovations it has shown.